Stifel Nicolaus Keeps Their Buy Rating on Urogen Pharma (URGN)
In a report released today, Derek Archila from Stifel Nicolaus reiterated a Buy rating on Urogen Pharma (URGN). The company’s shares closed last Wednesday at $21.04.
According to TipRanks.com, Archila is a 1-star analyst with an average return of -2.4% and a 35.9% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Madrigal Pharmaceuticals, and Pacira Pharmaceuticals.
Currently, the analyst consensus on Urogen Pharma is a Strong Buy with an average price target of $46.00, which is an 86.9% upside from current levels. In a report issued on April 5, Oppenheimer also maintained a Buy rating on the stock with a $45.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $39.98 and a one-year low of $13.12. Currently, Urogen Pharma has an average volume of 198.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
UroGen Pharma Ltd. is a clinical stage pharmaceutical company, which engages in the provision of non-surgical and localized solutions for urological pathologies to address a clinical unmet need in field of uro-oncology. Its pipeline includes upper tract urothelial carcinoma, low grade non muscle invasive bladder cancer, carcinoma in situ of the bladder, and overactive bladder. The company was founded by Asher Holzer in 2004 and is headquartered in New York, NY.